IPO bound? CRISPR Ther­a­peu­tics ups B round to a cool $140M

Gene edit­ing play­er CRISPR Ther­a­peu­tics just added a large­ly un­need­ed $38 mil­lion to its B round with a group of crossover in­vestors in tow — prob­a­bly sig­nal­ing that their S-1 is ei­ther ready to roll or in late-stage edit­ing.

Ver­tex Phar­ma­ceu­ti­cals and Bay­er Glob­al In­vest­ments – a col­lab­o­ra­tor – led the round, which brings the to­tal in the B round to a whop­ping $140 mil­lion.

Franklin Tem­ple­ton In­vest­ments, New Leaf Ven­ture Part­ners, funds ad­vised by Clough Cap­i­tal Part­ners L.P. and Welling­ton Cap­i­tal Man­age­ment L.L.P., and “oth­er undis­closed funds spe­cial­iz­ing in life sci­ences” all par­tic­i­pat­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER